These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 15243967)
21. How does HIV impact on non-AIDS events in the era of HAART? Barber TJ; Hughes A; Dinsmore WW; Phillips A Int J STD AIDS; 2009 Jan; 20(1):1-3. PubMed ID: 19103883 [TBL] [Abstract][Full Text] [Related]
22. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART. Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959 [TBL] [Abstract][Full Text] [Related]
23. Impact of depression on HIV outcomes in the HAART era. Hartzell JD; Janke IE; Weintrob AC J Antimicrob Chemother; 2008 Aug; 62(2):246-55. PubMed ID: 18456650 [TBL] [Abstract][Full Text] [Related]
24. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy. Matsukura M; Chu FF; Au M; Lu H; Chen J; Rietkerk S; Barrios R; Farley JD; Montaner JS; Montessori VC; Walker DC; Côté HC AIDS; 2008 Jun; 22(10):1226-9. PubMed ID: 18525271 [TBL] [Abstract][Full Text] [Related]
25. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient. De Rosa FG; Audagnotto S; Bargiacchi O; Garazzino S; Aguilar Marucco D; Veronese L; Canta F; Bonora S; Sinicco A; Di Perri G J Infect; 2006 Nov; 53(5):e215-8. PubMed ID: 16549201 [TBL] [Abstract][Full Text] [Related]
26. Effects of highly active antiretroviral therapy on paediatric metabolite levels. Rhoads MP; Smith CJ; Tudor-Williams G; Kyd P; Walters S; Sabin CA; Lyall EG HIV Med; 2006 Jan; 7(1):16-24. PubMed ID: 16313288 [TBL] [Abstract][Full Text] [Related]
27. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408 [TBL] [Abstract][Full Text] [Related]
28. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Vogel M; Rockstroh JK Curr Opin HIV AIDS; 2009 May; 4(3):171-5. PubMed ID: 19532046 [TBL] [Abstract][Full Text] [Related]
29. Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia. Huruy K; Mulu A; Mengistu G; Shewa-Amare A; Akalu A; Kassu A; Andargie G; Elias D; Torben W Jpn J Infect Dis; 2008 May; 61(3):205-9. PubMed ID: 18503170 [TBL] [Abstract][Full Text] [Related]
30. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme. Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763 [TBL] [Abstract][Full Text] [Related]
31. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702 [TBL] [Abstract][Full Text] [Related]
32. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999 [TBL] [Abstract][Full Text] [Related]
33. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan. Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398 [TBL] [Abstract][Full Text] [Related]
35. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
36. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F; Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870 [TBL] [Abstract][Full Text] [Related]
37. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM; Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141 [TBL] [Abstract][Full Text] [Related]
38. [Cutaneous drug reactions in HIV-infected patients in the HAART era]. Blanes M; Belinchón I; Portilla J Actas Dermosifiliogr; 2009 May; 100(4):253-65. PubMed ID: 19463228 [TBL] [Abstract][Full Text] [Related]
39. [Neurological manifestations of HIV-infection in the era of highly active antiretroviral therapy (HAART)]. Arendt G Fortschr Neurol Psychiatr; 2005 Oct; 73(10):577-86. PubMed ID: 16217698 [TBL] [Abstract][Full Text] [Related]